Diphenhydramine has not been proven to directly cause dementia, but the observational evidence linking heavy, long-term use to increased dementia risk is strong enough that major medical organizations now recommend older adults avoid it. The strongest study on the topic found that people who used anticholinergic drugs like diphenhydramine at high cumulative doses over a decade had roughly a 50 percent higher risk of developing dementia compared to non-users. That gap between “associated with” and “causes” matters, and it is where much of the scientific debate still lives.
What the Largest Studies Found
The most widely cited research comes from a prospective cohort study that tracked over 3,400 adults aged 65 and older for an average of about seven years. Researchers measured cumulative anticholinergic use, including diphenhydramine, using pharmacy dispensing records. People in the highest exposure group had a 54 percent higher risk of dementia and a 63 percent higher risk of Alzheimer’s disease specifically, compared to those who had not used anticholinergic drugs. The relationship followed a dose-response pattern: more cumulative use meant more risk, with a statistically significant trend across exposure categories.1JAMA Internal Medicine. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
A separate large study focused specifically on first-generation antihistamines, the class diphenhydramine belongs to, in patients with allergic rhinitis. It found the same dose-response pattern: at low cumulative doses, risk was elevated by about 13 percent, and at the highest doses, it climbed to 51 percent. The researchers tracked cumulative defined daily doses rather than just whether someone had ever taken the drug, which gives a more precise picture of how much exposure matters.2PubMed. Cumulative Dose Effects of H1 Antihistamine Use on the Risk of Dementia in Patients With Allergic Rhinitis
Both studies are observational, not randomized trials, which means they can show correlation but cannot prove that diphenhydramine itself is the thing producing the risk. An expert consensus panel reviewing the evidence stated that while cumulative anticholinergic use is associated with increased dementia risk, there is no conclusive evidence establishing diphenhydramine as a direct cause.3PubMed Central. Expert Consensus on the Use of Diphenhydramine for Short-Term Insomnia: Efficacy, Safety, and Clinical Applications That distinction is not just academic caution. It reflects genuine uncertainty about what is happening beneath the statistics.
Short-Term Cognitive Effects in Older Adults
Even setting aside the dementia question, diphenhydramine has well-documented effects on cognition in the short term, especially in people over 65. A study of hospitalized older patients found that those exposed to diphenhydramine had a 70 percent higher risk of cognitive decline during their hospital stay compared to unexposed patients. After adjusting for other factors, the odds of cognitive decline were more than doubled. Delirium symptoms were also far more common: the risk of inattention tripled, and the risk of altered consciousness roughly tripled as well. Higher doses made things worse, with a clear dose-response trend.4JAMA Network. Cognitive and Other Adverse Effects of Diphenhydramine Use in Hospitalized Older Patients
This matters because it illustrates something about how diphenhydramine acts on the brain. By blocking acetylcholine, a neurotransmitter critical to attention, memory formation, and overall alertness, the drug creates immediate and measurable cognitive disruption. In younger adults, the brain generally compensates and recovers quickly. In older adults, whose acetylcholine systems are already declining with age, the disruption can be severe enough to cause delirium or noticeable thinking problems that last for the duration of exposure and sometimes beyond. Whether years of such repeated disruption accumulate into permanent damage is exactly the question that the long-term studies are trying to answer.
What Brain Imaging Reveals
Some of the most striking evidence comes from neuroimaging studies. A study of cognitively normal older adults compared brain scans of those taking anticholinergic medications (including diphenhydramine) with those not taking them. The anticholinergic users had measurably smaller total cortical volume, thinner temporal lobes, and enlarged ventricles, all markers typically associated with brain aging and neurodegeneration. They also showed reduced glucose metabolism in the hippocampus, the brain region most critical for forming new memories and one of the first areas damaged in Alzheimer’s disease. Higher anticholinergic burden correlated with worse performance on tests of executive function.5PubMed Central. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults
A more recent study looking at anticholinergic burden across the Alzheimer’s disease spectrum found moderate evidence that higher burden was linked to worse baseline cognitive function, with some weaker evidence for faster decline in executive function over time. The picture for brain volumes, however, was less consistent: in that study, anticholinergic burden was not clearly associated with changes in hippocampal or basal forebrain volume over time.6PubMed Central. Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer’s disease spectrum This inconsistency is typical of the research landscape: the signal is there, but it is not uniform across every measure and every population. Structural brain changes do not automatically mean dementia is inevitable, but they do suggest that something more than short-lived side effects is happening.
Why Proving Causation Is So Difficult
The gap between “associated with dementia” and “causes dementia” is not just a polite hedge. There are real methodological problems that make it hard to draw firm conclusions from the available data.
The biggest issue is something called reverse causation. Dementia develops over many years before a diagnosis, and people in its earliest stages often experience sleep problems, anxiety, depression, and allergies in ways that lead them to use more over-the-counter medications, including diphenhydramine. If the disease itself is driving the medication use rather than the other way around, then the statistical association would appear even if diphenhydramine had no effect on dementia risk at all. Researchers have tried to address this by measuring drug exposure years before any dementia diagnosis, but early disease processes can begin a decade or more before symptoms appear, making it hard to be sure which came first.
There is also the problem of confounding by indication. People who take diphenhydramine regularly tend to have chronic insomnia, allergies, or anxiety. Poor sleep on its own is a well-established risk factor for cognitive decline. If researchers are not fully capturing the severity and duration of the sleep problems that drove people to take diphenhydramine in the first place, some of the apparent risk attributed to the drug could really belong to the underlying condition it was treating.
Randomized controlled trials would be the gold standard for settling this, but you cannot ethically assign thousands of people to take an anticholinergic drug for a decade to see if they develop dementia. That means we are likely stuck with observational evidence for the foreseeable future, and observational evidence by its nature leaves room for debate.
Who Faces the Greatest Risk
Not everyone who takes a Benadryl now and then faces the same level of concern. The evidence consistently points to cumulative exposure as the key variable: a single dose when you are sneezing is a very different situation from nightly use for years. The risk signal in the major studies becomes significant at months to years of regular use, not at occasional doses.
Age is the most important modifier. Older adults have lower acetylcholine levels to begin with, slower drug metabolism, and a blood-brain barrier that becomes more permeable over time. This is why the American Geriatrics Society’s Beers Criteria, a widely referenced list of medications that are best avoided in adults 65 and older, has included diphenhydramine for years.7PubMed Central. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults8PubMed. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
Sex and race also appear to matter. A population-based study found that women were more likely than men to receive anticholinergic medications, and that anticholinergic users overall had about 26 percent higher odds of cognitive impairment compared to non-users. The disparities in prescribing patterns are worth noting because they mean certain groups accumulate more anticholinergic exposure over time without necessarily being aware of it.9Neurology: Clinical Practice. Disparities in Cognitive Impairment With Anticholinergic Drug Use: A Population-Based Study
Polypharmacy, taking multiple medications simultaneously, amplifies the concern. A study of community-dwelling older adults in Italy found that those with a severe anticholinergic burden score had more than three times the odds of mild cognitive impairment compared to those with no anticholinergic exposure. The association was particularly strong for executive function, with odds roughly four and a half times higher. Many people do not realize that anticholinergic effects can stack: diphenhydramine, certain antidepressants, bladder medications, and muscle relaxants can all contribute to the same cumulative burden on the acetylcholine system.10PubMed Central. Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes
Second-Generation Antihistamines as Alternatives
One of the most practical takeaways from this research is that not all antihistamines carry the same concern. Diphenhydramine is a first-generation antihistamine, meaning it crosses the blood-brain barrier easily and blocks acetylcholine in the central nervous system. Second-generation antihistamines like cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra) were specifically designed to stay largely outside the brain. They treat allergies without the drowsiness, and they do not carry the same anticholinergic load.
A recent study using real-world data and a target trial emulation design compared second-generation antihistamine users with non-users and with first-generation antihistamine users. No increased dementia risk was found with second-generation antihistamines across any comparison.11The Journal of Allergy and Clinical Immunology: In Practice. Second-Generation H1-Antihistamines Do Not Alter Dementia Risk in Type 2 Inflammatory Diseases: A Target Trial Emulation Using Real-World Data For people who need regular allergy relief, the switch to a second-generation option is straightforward and removes the anticholinergic concern entirely.
Sleep is a different story. Many people reach for diphenhydramine not for allergies but for insomnia, and second-generation antihistamines are not sedating, so they are not a substitute for that purpose. If you are using diphenhydramine regularly to sleep, the conversation with your doctor should be about better sleep treatments altogether, not about swapping one antihistamine for another.
The Hidden Prevalence of Diphenhydramine in Sleep Products
Part of what makes this issue so relevant is that many people do not know they are taking diphenhydramine at all. The drug is the active ingredient in Benadryl, but it is also the sedating component in many over-the-counter sleep aids marketed under names like ZzzQuil, Tylenol PM, Advil PM, Unisom SleepGels, and generic “nighttime” formulations. A study of older adults found that over half of the 223 over-the-counter sleep products reported by participants contained diphenhydramine or the closely related drug doxylamine. Nearly 60 percent of participants had used a potentially inappropriate over-the-counter sleep medication within the past month, and those taking diphenhydramine-containing products were significantly less likely to be aware of any safety risks associated with them.12PubMed Central. Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep
The gap in awareness is striking. People who would never consider themselves “regular diphenhydramine users” may be taking it nightly in a product they think of as a simple sleep aid. Because these products are sold without a prescription, there is no pharmacist or physician review built into the purchase. This is especially concerning for older adults, for whom the Beers Criteria specifically recommend avoiding diphenhydramine.
Can Stopping Help?
If someone has been taking diphenhydramine or other anticholinergic drugs regularly and is worried about cognitive effects, one natural question is whether stopping the drug can reverse any damage. The evidence here is limited but cautiously encouraging. A Cochrane systematic review looked at deprescribing interventions that aimed to reduce anticholinergic medication use in older adults. The three trials included were small, with only 299 participants total, and outcomes were measured after just one to three months. One trial reported a small but significant improvement in a cognitive processing speed test among those whose anticholinergic burden was reduced.13PubMed Central. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment
That is a thin evidence base to build strong claims on. But it suggests that at least some of the cognitive effects of anticholinergic use may be reversible, at least in the short to medium term. Whether long-term structural brain changes visible on imaging can be reversed by stopping the drug is a question nobody has yet answered convincingly. The best available advice is that reducing anticholinergic burden is unlikely to cause harm and may produce some cognitive benefit, but it should be done in consultation with a healthcare provider rather than abruptly, especially if the medication is being used for a genuine medical condition.
How Diphenhydramine Compares to Other Anticholinergics
Diphenhydramine gets the most attention in this conversation because it is so widely available without a prescription, but it is not the only anticholinergic drug linked to cognitive concerns. The anticholinergic class includes certain tricyclic antidepressants, bladder control medications like oxybutynin, older antipsychotics, and some anti-nausea drugs. The research linking anticholinergic burden to dementia risk generally treats these drugs as a class, with the key variable being total anticholinergic load rather than any one specific drug.
The landmark prospective cohort study noted that participants in the highest cumulative exposure group were at similarly elevated risk for dementia regardless of whether their anticholinergic use came from antidepressants or other anticholinergic classes.1JAMA Internal Medicine. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study This is relevant because a person taking diphenhydramine nightly for sleep while also taking an anticholinergic bladder medication is accumulating anticholinergic burden from two sources simultaneously. The risk in the studies tracks with total burden, and someone whose doctor reviews their entire medication list might find that diphenhydramine is just one piece of a larger anticholinergic puzzle that can be simplified.
What Genetic Background Might Mean
Emerging research has explored whether certain people are genetically more vulnerable to anticholinergic-related cognitive harm. The APOE4 gene variant, which is the strongest known genetic risk factor for late-onset Alzheimer’s disease, appears to amplify the cognitive impact of anticholinergic drugs. People carrying APOE4 who also use anticholinergics seem to face steeper cognitive risks than those without the variant. Similarly, people who already have early Alzheimer’s pathology in their brains, such as amyloid plaques, may be more sensitive to the additional insult of acetylcholine suppression.
This makes biological sense: if your brain is already struggling with the plaques and tangles of Alzheimer’s disease, further reducing acetylcholine levels with a drug would be like turning down the lights in a room that is already dim. The clinical implication is that anticholinergic avoidance may be especially important for people who know they carry APOE4 or who have a strong family history of Alzheimer’s disease, though routine genetic testing for APOE status is not currently recommended for medication decisions.
Practical Implications for Different Age Groups
For younger adults who occasionally take diphenhydramine for a bad cold or an allergic reaction, the available evidence does not suggest meaningful long-term risk. The studies showing concerning associations involve years of cumulative exposure, primarily in people over 65 whose brains are more vulnerable to anticholinergic effects. A 30-year-old taking Benadryl for a week during allergy season is in a fundamentally different situation from a 70-year-old taking a diphenhydramine sleep aid every night for three years.
For adults in their 40s and 50s who use diphenhydramine regularly for sleep, the research creates a more uncomfortable uncertainty. It is not clear at what age the cumulative clock starts ticking in a clinically meaningful way. Given that dementia pathology can begin developing decades before diagnosis, erring toward caution makes sense if you are using the drug frequently. Switching to non-anticholinergic sleep strategies, whether behavioral approaches like cognitive behavioral therapy for insomnia or medications without anticholinergic activity, removes the concern entirely.
For adults 65 and older, the medical consensus is clear. Major geriatric medicine organizations explicitly recommend avoiding diphenhydramine. The short-term cognitive risks are well-established even apart from the dementia question, and the availability of safer alternatives for both allergies and sleep makes continued use hard to justify. If you are in this age group and currently taking a product that contains diphenhydramine, a pharmacist can often identify it during a medication review and suggest an appropriate substitute.